Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…Abstract Number: 1276 • 2019 ACR/ARP Annual Meeting
Myositis Specific Antibodies and Clinical Features in Patients from Argentina
Background/Purpose: To know the frequency of myositis specific antibodies (MSAs) and myositis associated antibodies( MAAs) and their relation with clinical features in patients with idiopathic…Abstract Number: 1278 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM), collectively known as idiopathic inflammatory myositis (IIM), are autoimmune disorders characterized by inflammation of skeletal muscle, especially in the…Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…Abstract Number: 1280 • 2019 ACR/ARP Annual Meeting
JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Background/Purpose: We previously observed in vitro that IFN-I reproduces dermatomyositis (DM) pathological findings, that pathogenic effects may be prevented in vitro by JAK inhibitor (JAKinh) therapy and an improvement…Abstract Number: 1285 • 2019 ACR/ARP Annual Meeting
Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course
Background/Purpose: Capillary abnormalities in the nail-fold are a characteristic finding of microangiopathy in autoimmune connective tissue diseases, including dermatomyositis and systemic sclerosis. A previous study…Abstract Number: 1347 • 2018 ACR/ARHP Annual Meeting
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: There is a lack of standardized methodology for assessing whole body MRI (WBMRI) in idiopathic inflammatory myopathy (IIM) patients. This leads to difficulty in…Abstract Number: 1382 • 2018 ACR/ARHP Annual Meeting
Evaluating Results of an Interferon-γ Release Assay in Patients with Autoimmune Skin Disease on Hydroxychloroquine
Background/Purpose: QuantiFERON-TB Gold is commercial interferon-γ release assay used to screen patients for tuberculosis before starting or while on immunosuppressive therapies. Clinical studies on efficacy…Abstract Number: 1851 • 2018 ACR/ARHP Annual Meeting
Physical Function Trajectories in Children with Juvenile Myositis
Background/Purpose: Juvenile myositis (JM) is an inflammatory disease that causes muscle weakness, skin rashes, and significant deconditioning. Little is known about long-term resolution of physical…Abstract Number: 2163 • 2018 ACR/ARHP Annual Meeting
Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years
Prevalence and Incidence of idiopathic Inflammatory Myopathies in Korea: a Nationwide Population-based Study over 10 yearsYoon-Kyoung Sung1, Hyoungyoung Kim1, Jisun Myung2, Eunwoo Nam2, Sun-young Jung3,…Abstract Number: 2287 • 2018 ACR/ARHP Annual Meeting
Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Background/Purpose: Cutaneous dermatomyositis (DM) is often refractory to multiple medications, suggesting better treatments are needed. Adrenocorticotropic hormone gel is a repository corticotropin injection that is…Abstract Number: 2291 • 2018 ACR/ARHP Annual Meeting
Longitudinal Course of the Disease in Anti-Mi2 Patients: More Intense Muscle Weakness, Good Response to Treatment and Progressive Reduction of Autoantibody Titers
Background/Purpose: Autoantibodies targeting the Mi-2 (Mi-2a and Mi-2b) nuclear antigen in patients with dermatomyositis (DM) were first described in 1985. However, little is known about…Abstract Number: 373 • 2018 ACR/ARHP Annual Meeting
The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data
Background/Purpose: Muscle inflammation and weakness, subsequent atrophy and permanent muscle damage in idiopathic inflammatory myopathies (IIM) lead to impaired function, reduced muscle strength, endurance and…Abstract Number: 377 • 2018 ACR/ARHP Annual Meeting
Preliminary Validation of Rectus Femoris Muscle Ultrasound in Idiopathic Inflammatory Myopathy Patients
Background/Purpose: Muscle ultrasound (MUS) offers a cost effective, accessible option for detection of muscle inflammation and atrophy in patients with Idiopathic Inflammatory Myopathies (IIM). The…Abstract Number: 379 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS),…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 24
- Next Page »